文献速递皮肤肿瘤

一项随机、多国、非劣效性III期试验:评估BF-200氨基乙酰丙酸凝胶与甲基氨基乙酰丙酸酯乳膏在光动力疗法治疗非侵袭性基底细胞癌中的安全性和疗效

A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy.
PubMed 文献 · Br J Dermatol · 2018-05-16

这项在德国和英国开展的随机III期非劣效性试验纳入281例非侵袭性基底细胞癌患者,分别接受BF-200氨基乙酰丙酸凝胶(138例)或甲基氨基乙酰丙酸酯乳膏(143例)光动力疗法。末次光动力疗法后12周,BF-200组完全缓解率为93.4%,MAL组为91.8%,差值1.6(单侧97.5%CI -6.5),证实非劣效性(P<0.0001)。

要点

  • BF-200 ALA-PDT治疗非侵袭性基底细胞癌完全缓解率93.4%,MAL-PDT为91.8%。
  • 两组完全缓解率差值1.6,单侧97.5%CI -6.5,在Δ=-15%界值内证实非劣效性(P<0.0001)。
  • 末次治疗后12个月复发率≤10%,BF-200 ALA-PDT高效且耐受性良好。

核心结论

  • BF-200 ALA-PDT治疗非侵袭性基底细胞癌高度有效且耐受性良好,证实对MAL-PDT非劣效,随访1年复发率低。

研究设计与样本

  • 随机、III期非劣效性试验,在德国和英国开展,计划随访5年。
  • 281例随机患者中,138例接受BF-200 ALA治疗,143例接受MAL治疗。
  • 患者接受两次光动力疗法,间隔1周;第二次光动力疗法后12周仍有残留病灶者接受重复治疗。
  • 光照采用红光光源(635 nm,37 J cm-2)。
  • 研究在EudraCT注册(编号2013-003241-42)。

主要发现

  • BF-200 ALA组完全缓解率93.4%,MAL组91.8%。
  • 两组差值1.6,单侧97.5%CI -6.5,证实非劣效性(P<0.0001)。
  • 次要疗效参数结果与主要结局一致。
  • 末次治疗后12个月复发率≤10%。

关键数值与推荐

  • 非劣效性界值Δ=-15%,若BF-200 ALA平均缓解率不劣于MAL超过该界值则判定非劣效。
  • 主要疗效变量为末次光动力疗法后12周总体患者完全缓解率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Basal cell carcinoma (BCC) represents the most common nonmelanoma skin cancer worldwide, affecting mainly adult, fair-skinned individuals. The World Health Organization distinguishes aggressive and nonaggressive forms, of which prototypical variants of the latter are primary nodular and superficial BCC. OBJECTIVES: To demonstrate noninferiority of BF-200 ALA (a nanoemulsion gel containing 5-aminolaevulinic acid) compared with MAL (a cream containing methyl aminolaevulinate) in the treatment of nonaggressive BCC with photodynamic therapy (PDT). Noninferiority of the primary efficacy variable (overall patient complete response 12 weeks after last PDT) would be declared if the mean response for BF-200 ALA was no worse than that for MAL, within a statistical margin of Δ = -15%. METHODS: The study was a randomized, phase III trial performed in Germany and the U.K. with ongoing 5-year follow-up. Of 281 randomized patients, 138 were treated with BF-200 ALA and 143 with MAL. Patients received two PDT sessions 1 week apart. Remaining lesions 12 weeks after the second PDT were retreated. Illumination was performed with a red light source (635 nm, 37 J cm-2 ). The results shown include clinical end points and patients' reassessment 12 months after the last PDT. The study was registered with EudraCT (number 2013-003241-42). RESULTS: Of the BF-200 ALA-treated patients, 93·4% were complete responders compared with 91·8% in the MAL group. The difference of means was 1·6, with a one-sided 97·5% confidence interval of -6·5, establishing noninferiority (P < 0·0001). The results for secondary efficacy parameters were in line with the primary outcome. Recurrence rates 12 months after the last treatment were ≤ 10%. CONCLUSIONS: Treatment of nonaggressive BCC with BF-200 ALA-PDT is highly effective and well tolerated with proven noninferiority to MAL-PDT. It demonstrates low recurrence rates after 1 year of follow-up.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Morton CA, Dominicus R, Radny P, et al. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. Br J Dermatol. 2018. PMID: 29432644. doi:10.1111/bjd.16441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。